IIT

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results

Retrieved on: 
Thursday, March 28, 2024
Stony Brook University, University, Adenocarcinoma, PRRT, Patient, Mayo Clinic, Sale, Bristol Myers Squibb, Society, IND, European Journal, Therapy, SPECT, Melanoma, Research, MC1R, Fortis Healthcare, SNMMI, Cohort, Trial of the century, Radiopharmaceutical, Cancer, Nivolumab, Safety, CATX, PSMA, Food, LNTH, BMY, IIT, Prostate cancer, Nuclear medicine, EANM, NETS, Institute of technology, Diagnosis, Glomus tumor, PET, Prostate, Small business, Bangladesh Technical Education Board, Molecular imaging, Pharmaceutical industry

SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced fiscal year 2023 financial results for the period ended December 31, 2023.

Key Points: 
  • SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced fiscal year 2023 financial results for the period ended December 31, 2023.
  • “We made tremendous progress during 2023 in building a fully integrated radiopharmaceuticals company dedicated to advancing potentially best- or first-in-class alpha-particle therapies,” said Thijs Spoor, Perspective Therapeutics' CEO.
  • Preliminary results from Cohorts 1 and 2 of the Phase 1/2a trial are expected in the third quarter 2024.
  • In January 2024, Perspective Therapeutics entered into strategic agreements with Lantheus Holdings, Inc. and its affiliates (“Lantheus”) (NASDAQ: LNTH).

BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer

Retrieved on: 
Monday, March 25, 2024
IIT, Radiation, IO, Carcinoma, Survival, NSCLC, Entrepreneurship, Monroe Dunaway Anderson, Patient, Journal, Merck, Overalls, MD, Lung, Neoplasm, Safety, EP, SITC, PFS, PD-L1, Platinum, Horn, Immunotherapy, PD-1, Medical imaging

This Phase 2 trial will evaluate the efficacy and safety of Pembrolizumab, Plinabulin plus EP in 1L ES-SCLC.

Key Points: 
  • This Phase 2 trial will evaluate the efficacy and safety of Pembrolizumab, Plinabulin plus EP in 1L ES-SCLC.
  • KEYNOTE-604 study revealed that 12-month PFS rate in patients with pembrolizumab plus EP is 13.6% vs. 3.1% with placebo plus EP.
  • Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell Lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
  • An Open-Label, Single-Arm, Phase II Study of Pembrolizumab, Plinabulin Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer.

Phosphorus Appoints Osama AlZoubi as Regional Vice President of Saudi Arabia and Middle East

Retrieved on: 
Wednesday, March 13, 2024
IIT, Organization, NEOM, CPS, Growth, Computer science, Red Sea Project, Digital, Internet of things, RSAC, DEF, Industrial internet of things, Knowledge, Artificial intelligence, Business architecture, University, Software, Engineering, System, IoMT, Kingdom, Digital transformation, Vision 2030, City, Publication, Cisco, OT, Destroy Lonely, Public sector, Patent, Region, UIC, MEA, Cyber-physical system, Computer, ICT, Arms industry

NASHVILLE, Tenn., March 13, 2024 (GLOBE NEWSWIRE) -- Phosphorus Cybersecurity Inc., the leading provider of unified, prevention-based security management for the xTended Internet of Things (xIoT), today announced the appointment of Osama AlZoubi as the Regional Vice President, Saudi Arabia and the Middle East.

Key Points: 
  • NASHVILLE, Tenn., March 13, 2024 (GLOBE NEWSWIRE) -- Phosphorus Cybersecurity Inc., the leading provider of unified, prevention-based security management for the xTended Internet of Things (xIoT), today announced the appointment of Osama AlZoubi as the Regional Vice President, Saudi Arabia and the Middle East.
  • As one of the world’s fastest growing economic regions, Saudi Arabia and the Middle East are experiencing significant technological progress, particularly in energy, smart manufacturing, and urban development.
  • “Cybersecurity is critically important in fast-developing Saudi Arabia, and across the Middle East region, as more countries invest in advanced technologies, such as smart cities.
  • Prior to joining Phosphorus, AlZoubi held multiple global leadership roles and most recently served as Chief Technology Officer (CTO) for Cisco in the Middle East and Africa.

DIGITIMES Asia: India's homegrown microprocessors claim 'generation minus one' benchmarking

Retrieved on: 
Wednesday, April 3, 2024
ISA, IIT, Health, SOC, Development, Benchmarking, Growth, IIT Madras, Agriculture, Internet of things, Information technology, PDK, Software, Linux, Coremark, Student, Architecture, Publication, Education minister, Traction, Ecosystem, Multimedia, Ministry, Government, Silicon, C-DAC, Video game

"Regarding the benchmarking, we're operating at what you could call "generation minus one" compared to the latest contemporary microprocessors," Kamakoti said, in a recent conversation with Digitimes Asia.

Key Points: 
  • "Regarding the benchmarking, we're operating at what you could call "generation minus one" compared to the latest contemporary microprocessors," Kamakoti said, in a recent conversation with Digitimes Asia.
  • "The benchmarks depend on various factors, including the specific silicon and Process Development Kit (PDK) used," Kamakoti continued.
  • "We're very close to, and in some cases better than, contemporary microprocessors according to benchmarks like CoreMark, which is widely used for embedded systems.
  • Several startups in India are now leveraging Shakti for various applications, from security to SoC development, highlighting the architecture's flexibility and adaptability to specific needs.

Four Seasons Hotels and Resorts Appoints Sudhakar Veluru as Executive Vice President and Chief Information Technology Officer

Retrieved on: 
Monday, March 25, 2024
Master of Engineering, IIT, Arizona State University, Information technology, Enterprise architecture, Business administration, Vacation Club, Sudhakar, University, MBA, PMP, The Walt Disney Company, Project Management Professional, MGM, MGM Resorts International, Management

TORONTO, March 25, 2024 /PRNewswire/ -- Four Seasons , the world's leading luxury hospitality company, is pleased to announce the appointment of Sudhakar Veluru as the company's new Executive Vice President and Chief Information Technology Officer (CITO), effective March 25, 2024.

Key Points: 
  • TORONTO, March 25, 2024 /PRNewswire/ -- Four Seasons , the world's leading luxury hospitality company, is pleased to announce the appointment of Sudhakar Veluru as the company's new Executive Vice President and Chief Information Technology Officer (CITO), effective March 25, 2024.
  • Sudhakar will join Four Seasons Executive Leadership Team reporting to Alejandro Reynal , President and CEO, Four Seasons.
  • "We are excited to welcome Sudhakar at this important time in Four Seasons information technology transformation," says Reynal.
  • With an impressive career spanning over two decades, Sudhakar brings a wealth of experience and expertise in driving digital and information technology transformation initiatives within the hospitality and technology sectors.

CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair

Retrieved on: 
Monday, March 4, 2024
IIT, Regenerative medicine, Research, Microsoft Exchange Server, News, Ageing, Cancer, GMP, Cartilage, Cell, National University Hospital, SingHealth, SKH, B cell, Safety, UC, Transplant, Knee, Patient, Clinical trial, Osteoarthritis, MSC, Umbilical cord, RCA, Pharmaceutical industry

Osteoarthritis of the knee is a debilitating disease affecting Singapore’s aging population and the clinical trial will pioneer stem cell use for regenerative medicine in Singapore.

Key Points: 
  • Osteoarthritis of the knee is a debilitating disease affecting Singapore’s aging population and the clinical trial will pioneer stem cell use for regenerative medicine in Singapore.
  • UC-MSCs are a type of adult stem cells that can be isolated from the umbilical cord tissue after childbirth.
  • UC-MSCs are considered multipotent and are able to differentiate into different cell types, including bone, cartilage, fat, and muscle cells.
  • "Our collaboration with CytoMed marks a significant step in advancing research on allogeneic in-vivo UC-MSC for cartilage repair, including osteoarthritis of the knee.

LTIMindtree Joins Forces with IBM to Advance the Quantum Innovation Ecosystem

Retrieved on: 
Wednesday, February 28, 2024
Technology, Finance, Semiconductor, Consulting, Other Technology, Professional Services, Software, Hardware, Data Management, IIT, Research, IIT Madras, Platinum, IBM, GSI, Business development, University, LTIMindtree

LTIMindtree is the first Indian Global System Integrator (GSI) to join the IBM Quantum Network.

Key Points: 
  • LTIMindtree is the first Indian Global System Integrator (GSI) to join the IBM Quantum Network.
  • LTIMindtree will also collaborate with the Indian Institute of Technology (IIT) Madras, which is also an IBM Quantum Innovation Center, on joint quantum research and workforce development.
  • Scott Crowder, Vice President of IBM Quantum Adoption and Business Development, said, “We are excited to welcome LTIMindtree into the IBM Quantum Network and to help them explore the benefits of quantum computing, both for their internal teams and in solutions for their clients.
  • We are also looking forward to providing technology support for LTIMindtree’s joint research and educational engagements with IIT-Madras, our first IBM Quantum Innovation Center in India.”
    As part of the IBM Quantum Network, LTIMindtree expands on its platinum partner status with IBM and joins a global community of Fortune 500 companies, top universities, research labs, and startups.

Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis

Retrieved on: 
Friday, March 8, 2024
IIT, Division, Nervous system, Neurology, CD19, Stanford University, Multiple sclerosis, Safety, KYSA, Patient, Medicine, Knowledge, DSM-IV codes, Pharmaceutical industry

EMERYVILLE, Calif., March 7, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today announced the signature of a collaboration agreement with Stanford University to allow the use of KYV-101, an investigational, anti-CD19 CAR T-cell therapy in an open label, phase 1 investigator-initiated trial (IIT) in nine to twelve adult subjects with non-relapsing and progressive forms of multiple sclerosis. Each participant will receive a single dose of KYV-101.

Key Points: 
  • "We are grateful for the opportunity to join forces with Kyverna to explore what may prove to be paradigm-changing immunotherapy.".
  • "We are excited about the interest shown by world-class institutions like Stanford to evaluate the clinical performance of KYV-101 in patients suffering from multiple sclerosis," said Peter Maag, Ph.D., chief executive officer of Kyverna.
  • CAR T-cell therapy involves modifying a patient's T cells to recognize and remove B cells in the patient's body.
  • Kyverna plans to continue to explore additional indications for KYV-101 and develop a robust pipeline of promising product candidate immunotherapies aimed at addressing unmet medical needs in autoimmune diseases.

Immunofoco Announces the Dual Approval of IND Applications by the U.S. FDA and China CDE for the First EpCAM CAR-T Targeted at Advanced Solid Tumors

Retrieved on: 
Friday, February 23, 2024
IIT, ESMO, ASCO, FDA, GEJ, Acceptability, ODD, Stomach, GC, Society, GI, Bone marrow, Patient, Clinical trial, CDE, Oncology, IND, Chinese, Epithelial cell adhesion molecule, Pharmaceutical industry

SHANGHAI, Feb. 22, 2024 /PRNewswire/ -- Immunofoco, a company dedicated to developing cell therapy products for solid tumors, announced a significant milestone, that following the approval by the CDE in China for the clinical trial application of IMC001, an EpCAM-targeting autologous CAR-T cell product for infusion, it also received the IND approval from the U.S. FDA, for the treatment of EpCAM-positive advanced gastrointestinal tumors, including but not limited to advanced gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJ).

Key Points: 
  • EpCAM serves as a biomarker for circulating tumor cells (CTCs), which is highly expressed in both primary and metastatic lesions of gastrointestinal tumors, while its expression in normal tissues is low.
  • IMC001, through targeting EpCAM, is the first CAR-T product utilizing the strategy of "curing the solid tumors by treating them as hematologic malignancies ".
  • She highlighted the significance of Immunofoco's achievement: securing dual IND approval for a second CAR-T product targeted for solid tumors in both the U.S. and China.
  • Targeting EpCAM shows great potential for CAR-T treatment of solid tumors as it is highly expressed in primary, metastatic and circulating tumor cells.

AstraZeneca expands US manufacturing footprint to accelerate ambitions in next-generation cell therapy discovery and development

Retrieved on: 
Tuesday, February 6, 2024
Biotechnology, Pharmaceutical, Other Manufacturing, Oncology, General Health, Health, Manufacturing, Clinical Trials, Partnership, Multimedia, Prostate cancer, Cell, Environment, Patient, University, TP53, Ecosystem, Quell, Glypican, IIT, AstraZeneca, Physician, Arm, Acquisition, STEAP2, GPC3, Cancer, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240206590080/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240206590080/en/
    New AstraZeneca facility in Rockville, Maryland (Photo: Business Wire)
    The site represents the latest investment in cell therapy for AstraZeneca following collaborations with Quell therapeutics , AbelZeta, Cellectis , and the acquisition of Neogene Therapeutics.
  • In the US, AstraZeneca’s manufacturing sites focus on the production of small molecules and biologics, harnessing leading pharmaceutical technology and development.
  • AstraZeneca is building a cell therapy portfolio that aims to empower and equip the immune system’s T-cells to more effectively fight cancer.
  • Beyond this, the company is advancing a pipeline of novel T-cell receptor therapies (TCR-Ts) through Neogene Therapeutics, a wholly owned subsidiary of AstraZeneca.